Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free RZLT Stock Alerts

Rezolute (RZLT) Financials

Rezolute logo
$4.74 -0.01 (-0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$4.76 +0.01 (+0.32%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Rezolute

Annual Income Statements for Rezolute

This table shows Rezolute's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -21 -24 -30 -33 -61 -21 -41 -52 -68 -74
Consolidated Net Income / (Loss)		 -11 -15 -20 -30 -30 -20 -21 -41 -52 -68 -74
Net Income / (Loss) Continuing Operations		 -22 -30 -41 -56 -30 -20 -21 -41 -52 -68 -74
Total Pre-Tax Income 		-22 -30 -41 -56 -30 -20 -21 -41 -52 -68 -74
Total Operating Income		 -21 -30 -41 -55 -26 -21 -23 -42 -56 -70 -80
Total Gross Profit		 -6.38 -9.61 -14 -23 -21 -8.26 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 -2.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 6.38 9.61 14 20 21 8.26 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 15 20 26 32 4.49 12 23 42 56 70 80
Selling, General & Admin Expense		 7.34 6.85 11 9.86 1.34 1.17 7.91 9.36 12 15 18
Research & Development Expense		 5.44 11 13 17 0.67 3.21 15 32 44 56 62
Total Other Income / (Expense), net		 -0.66 0.02 0.05 -1.13 -4.50 0.19 1.99 0.78 4.21 1.96 5.48
Interest & Investment Income		 0.00 0.00 0.04 0.14 0.46 0.19 -0.31 -1.73 4.21 4.87 5.48
Other Income / (Expense), net		 -0.66 0.02 0.01 0.03 - 0.00 2.30 4.28 0.00 -2.91 0.00
Basic Earnings per Share		 ($0.54) ($0.84) ($0.57) ($0.54) ($18.41) ($3.54) ($2.72) ($2.26) ($1.01) ($1.33) ($0.98)
Weighted Average Basic Shares Outstanding		 20.95M 24.77M 41.30M 55.66M 1.78M 5.75M 7.67M 18.20M 51.19M 51.47M 76.00M
Diluted Earnings per Share		 ($0.54) ($0.84) ($0.57) ($0.54) ($18.41) ($3.54) ($2.72) ($2.32) ($1.01) ($1.33) ($0.98)
Weighted Average Diluted Shares Outstanding		 20.95M 24.77M 41.30M 55.66M 1.78M 5.75M 7.67M 19.49M 51.19M 51.47M 76.00M
Weighted Average Basic & Diluted Shares Outstanding		 20.95M 24.77M 41.30M 55.66M 1.78M 5.75M 7.67M 38.83M 36.83M 55.37M 90.81M

Quarterly Income Statements for Rezolute

This table shows Rezolute's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -14 -17 -23 -15 -16 -19 -24 -18 -23 -16
Consolidated Net Income / (Loss)		 -15 -14 -17 -23 -15 -16 -19 -24 -18 -23 -16
Net Income / (Loss) Continuing Operations		 -15 -14 -17 -23 -15 -16 -19 -24 -18 -23 -16
Total Pre-Tax Income 		-15 -14 -17 -23 -15 -16 -19 -24 -18 -23 -16
Total Operating Income		 -16 -15 -16 -23 -17 -17 -20 -26 -20 -24 -17
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 16 15 16 23 17 17 20 26 20 24 17
Selling, General & Admin Expense		 3.70 3.16 3.81 4.01 4.19 4.45 4.74 4.99 6.67 9.87 5.95
Research & Development Expense		 12 12 12 19 13 13 15 21 13 14 11
Total Other Income / (Expense), net		 1.39 1.29 -0.84 0.13 1.56 1.35 1.11 1.46 1.67 1.45 1.20
Interest & Investment Income		 1.40 1.30 1.12 1.04 1.58 1.34 1.12 1.45 1.68 1.45 1.20
Other Income / (Expense), net		 -0.01 -0.02 -1.96 -0.92 -0.02 0.01 -0.01 0.02 -0.02 0.00 0.00
Basic Earnings per Share		 ($0.28) ($0.27) ($0.34) ($0.44) ($0.22) ($0.22) ($0.27) ($0.27) ($0.18) ($0.22) ($0.16)
Weighted Average Basic Shares Outstanding		 51.41M 51.41M 50.81M 51.47M 69.74M 69.94M 70.03M 76.00M 103.42M 103.69M 104.04M
Diluted Earnings per Share		 ($0.28) ($0.27) ($0.34) ($0.44) ($0.22) ($0.22) ($0.27) ($0.27) ($0.18) ($0.22) ($0.16)
Weighted Average Diluted Shares Outstanding		 51.41M 51.41M 50.81M 51.47M 69.74M 69.94M 70.03M 76.00M 103.42M 103.69M 104.04M
Weighted Average Basic & Diluted Shares Outstanding		 39.63M 39.63M 40.14M 55.37M 57.94M 60.54M 85.52M 90.81M 92.73M 95.70M 96.29M

Annual Cash Flow Statements for Rezolute

This table details how cash moves in and out of Rezolute's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -0.66 -1.22 0.42 -2.84 9.93 -1.62 31 120 -134 54 24
Net Cash From Operating Activities		 -7.08 -10 -13 -14 -15 -24 -20 -40 -44 -57 -69
Net Cash From Continuing Operating Activities		 -7.08 -10 -13 -14 -15 -24 -20 -40 -44 -57 -69
Net Income / (Loss) Continuing Operations		 -11 -15 -20 -30 -30 -20 -21 -41 -52 -68 -74
Consolidated Net Income / (Loss)		 -11 -15 -20 -30 -30 -20 -21 -41 -52 -68 -74
Depreciation Expense		 0.13 0.74 1.11 1.07 0.05 0.02 0.01 0.01 0.03 0.04 0.03
Amortization Expense		 0.01 0.01 0.01 - 2.05 - 0.00 2.50 -1.37 -2.84 -2.39
Non-Cash Adjustments To Reconcile Net Income		 3.50 3.81 6.01 14 13 -3.05 0.76 -0.42 7.63 11 7.65
Changes in Operating Assets and Liabilities, net		 0.64 -0.12 -0.16 1.03 -0.14 -0.83 -0.31 -0.64 1.02 3.10 0.05
Net Cash From Investing Activities		 -3.61 -1.45 -0.20 1.73 0.23 0.00 0.00 0.00 -101 49 -15
Net Cash From Continuing Investing Activities		 -3.61 -1.45 -0.20 1.73 0.23 0.00 0.00 0.00 -101 49 -15
Purchase of Investments		 - - - - - - - 0.00 -107 -66 -128
Sale and/or Maturity of Investments		 - - - - - - - 0.00 6.00 115 114
Net Cash From Financing Activities		 10 11 14 9.54 25 23 52 149 12 63 107
Net Cash From Continuing Financing Activities		 10 11 14 9.54 25 23 52 160 12 63 107
Repurchase of Common Equity		 -1.07 -0.89 -0.68 -0.06 0.00 -1.50 - - 0.00 -0.32 -1.06
Issuance of Common Equity		 11 5.36 15 4.50 0.00 24 41 180 12 63 107
Other Financing Activities, net		 -0.07 -0.09 -0.02 0.00 25 0.00 -3.73 -3.72 -0.76 0.23 0.89

Quarterly Cash Flow Statements for Rezolute

This table details how cash moves in and out of Rezolute's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.98 4.45 -6.57 64 -60 -1.54 5.66 80 -85 2.85 -0.71
Net Cash From Operating Activities		 -11 -13 -15 -19 -16 -14 -17 -22 -17 -20 -14
Net Cash From Continuing Operating Activities		 -11 -13 -15 -19 -16 -14 -17 -22 -17 -20 -14
Net Income / (Loss) Continuing Operations		 -15 -14 -17 -23 -15 -16 -19 -24 -18 -23 -16
Consolidated Net Income / (Loss)		 -15 -14 -17 -23 -15 -16 -19 -24 -18 -23 -16
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 0.97 -2.15 -0.92 -0.74 -0.83 -0.73 -0.50 -0.34 -0.80 -0.71 -0.48
Non-Cash Adjustments To Reconcile Net Income		 1.99 2.00 3.99 2.81 1.54 1.57 2.05 2.48 2.69 3.55 4.57
Changes in Operating Assets and Liabilities, net		 0.97 1.03 -1.27 2.37 -1.35 1.21 -0.04 0.23 -1.18 -0.40 -1.66
Net Cash From Investing Activities		 2.61 18 8.67 20 -49 11 23 0.35 -68 23 12
Net Cash From Continuing Investing Activities		 2.61 18 8.67 20 -49 11 23 0.35 -68 23 12
Purchase of Investments		 -16 -24 -17 -9.67 -73 -25 -2.02 -27 -89 -27 -37
Sale and/or Maturity of Investments		 19 42 25 29 24 37 25 28 20 50 49
Net Cash From Financing Activities		 0.00 -0.29 -0.00 63 5.50 0.66 0.01 101 0.91 0.36 0.75
Net Cash From Continuing Financing Activities		 0.00 -0.29 -0.00 63 5.50 0.66 0.01 101 0.91 0.36 0.75
Other Financing Activities, net		 0.00 - - 0.21 0.08 0.68 0.01 0.13 0.95 0.36 0.75

Annual Balance Sheets for Rezolute

This table presents Rezolute's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 11 11 11 2.50 12 11 43 152 124 133 175
Total Current Assets		 6.12 4.49 4.93 2.01 12 11 42 152 105 129 171
Cash & Equivalents		 5.28 4.06 4.49 1.65 12 9.96 41 150 16 70 94
Short-Term Investments		 - - - - - - - 0.00 86 56 74
Prepaid Expenses		 - - - 0.36 0.57 0.56 0.95 1.69 3.01 1.78 3.29
Plant, Property, & Equipment, net		 4.52 5.98 5.33 0.37 0.04 0.03 0.03 0.02 0.14 0.10 0.07
Total Noncurrent Assets		 0.62 0.43 0.37 0.13 0.06 0.41 0.59 0.30 19 3.98 4.27
Other Noncurrent Operating Assets		 0.56 0.38 0.33 0.09 0.04 0.41 0.59 0.30 2.20 3.72 4.27
Total Liabilities & Shareholders' Equity		 11 11 11 2.50 12 11 43 152 124 133 175
Total Liabilities		 2.21 2.13 2.10 6.46 11 3.60 17 2.95 7.55 12 13
Total Current Liabilities		 1.71 1.73 1.77 6.25 8.38 3.23 1.97 2.46 5.20 9.61 12
Accounts Payable		 1.41 1.50 0.95 1.85 0.56 0.89 1.04 1.13 3.27 4.90 5.81
Accrued Expenses		 - - 0.70 - 0.00 0.19 0.24 1.22 0.51 2.33 3.20
Current Employee Benefit Liabilities		 - - - 0.77 0.79 0.12 0.08 0.00 0.88 1.81 2.27
Other Current Liabilities		 0.13 0.13 0.11 0.19 7.03 2.03 0.61 0.11 0.54 0.57 0.63
Total Noncurrent Liabilities		 0.50 0.40 0.33 0.22 2.12 0.37 15 0.49 2.35 2.13 1.45
Other Noncurrent Operating Liabilities		 0.48 0.40 0.33 0.22 2.12 0.37 0.57 0.49 2.35 2.13 1.45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.05 8.77 8.53 -3.96 1.75 7.37 26 149 116 121 162
Total Preferred & Common Equity		 9.05 8.77 8.53 -3.96 1.75 7.37 26 149 116 121 162
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 9.05 8.77 8.53 -3.96 1.75 7.37 26 149 116 121 162
Common Stock		 38 53 73 90 129 155 194 359 378 451 566
Retained Earnings		 -29 -44 -64 -94 -127 -147 -168 -209 -261 -329 -404
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - 0.00 -0.35 -0.08 -0.01

Quarterly Balance Sheets for Rezolute

This table presents Rezolute's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 113 102 88 123 112 95 159 139 125
Total Current Assets		 103 96 82 110 99 89 155 135 122
Cash & Equivalents		 8.06 13 5.93 10 8.93 15 9.10 12 11
Short-Term Investments		 91 80 74 98 88 72 143 121 109
Prepaid Expenses		 3.92 3.49 2.19 1.91 2.15 1.84 2.51 2.17 1.78
Plant, Property, & Equipment, net		 0.13 0.12 0.11 0.10 0.09 0.08 0.06 0.06 0.05
Total Noncurrent Assets		 10 5.95 5.42 13 13 5.92 3.89 3.47 3.36
Other Noncurrent Operating Assets		 2.08 2.59 3.84 3.59 4.45 4.41 3.89 3.47 3.36
Total Liabilities & Shareholders' Equity		 113 102 88 123 112 95 159 139 125
Total Liabilities		 9.44 10 17 9.97 12 12 11 11 8.63
Total Current Liabilities		 7.20 8.01 6.96 7.99 11 11 10 9.53 7.70
Accounts Payable		 2.43 3.59 3.50 2.18 3.15 6.50 3.26 3.78 3.20
Accrued Expenses		 2.56 1.39 2.03 2.58 2.88 2.37 2.98 3.55 2.80
Current Employee Benefit Liabilities		 1.68 2.48 0.88 2.65 3.98 1.04 3.32 1.53 1.03
Other Current Liabilities		 0.53 0.54 0.55 0.58 0.60 0.62 0.65 0.67 0.67
Total Noncurrent Liabilities		 2.24 2.41 9.92 1.98 1.81 1.64 1.29 1.10 0.92
Other Noncurrent Operating Liabilities		 2.24 2.41 9.92 1.98 1.81 1.64 1.29 1.10 0.92
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 104 92 71 113 100 83 147 128 117
Total Preferred & Common Equity		 104 92 71 113 100 83 147 128 117
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 104 92 71 113 100 83 147 128 117
Common Stock		 379 381 377 458 460 462 569 573 578
Retained Earnings		 -276 -289 -306 -345 -361 -379 -422 -445 -461
Accumulated Other Comprehensive Income / (Loss)		 -0.28 -0.05 -0.08 0.29 0.06 0.04 0.05 0.05 -0.12

Annual Metrics And Ratios for Rezolute

This table displays calculated financial ratios and metrics derived from Rezolute's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 24,338,219.00 24,338,219.00 47,678,640.00 62,166,319.00 210,389,859.00 293,320,891.00 8,352,277.00 33,582,831.00 36,827,567.00 - 85,519,318.00
DEI Adjusted Shares Outstanding		 24,338,219.00 24,338,219.00 47,678,640.00 62,166,319.00 210,389,859.00 293,320,891.00 8,352,277.00 33,582,831.00 36,827,567.00 - 85,519,318.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.47 -0.86 -0.50 -0.48 -0.16 -0.21 -2.50 -1.22 -1.42 - -0.87
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -219.10% -32.87% -35.67% -36.69% 55.87% 14.00% -0.36% -70.36% -63.55% -32.79% -8.05%
EBIT Growth		 -107.04% -35.47% -35.99% -35.56% 52.90% 20.90% -0.34% -82.43% -49.06% -30.97% -8.95%
NOPAT Growth		 -107.37% -39.76% -35.94% -35.59% 52.93% 20.90% -11.56% -82.77% -33.81% -25.78% -13.45%
Net Income Growth		 -16.77% -31.45% -35.76% -47.27% -1.96% 33.22% -2.80% -96.44% -26.13% -32.19% -8.70%
EPS Growth		 48.08% -55.56% 32.14% 5.26% -3,309.26% 80.77% 23.16% 14.71% 56.47% -31.68% 26.32%
Operating Cash Flow Growth		 -123.50% -48.17% -26.91% -6.02% -8.44% -57.92% 15.42% -93.81% -12.28% -28.97% -20.41%
Free Cash Flow Firm Growth		 -129.66% -23.83% -24.62% -16.81% 67.51% -105.44% 18.34% -66.32% -29.34% -19.55% -24.19%
Invested Capital Growth		 547.00% 36.82% -15.70% -153.57% -352.16% 73.63% 62.16% 4.18% -133.65% -179.58% 6.57%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -5.78% -4.97% -13.47% -16.95% 63.57% -688.58% -40.77% 5.68% -11.88% -14.93% -1.75%
EBIT Q/Q Growth		 -5.90% -5.68% -13.08% -16.52% 60.54% -683.84% -40.73% -1.03% -5.54% -15.45% -2.33%
NOPAT Q/Q Growth		 -5.22% -5.47% -13.08% -16.56% 60.54% -683.84% -56.48% -12.54% -5.54% -14.40% -3.56%
Net Income Q/Q Growth		 -10.01% -5.89% -12.91% -26.75% 23.48% -2.01% -16.39% -7.69% -6.82% -17.60% -1.94%
EPS Q/Q Growth		 -74.19% -44.83% 30.49% -17.39% -2,568.12% 83.04% -7.09% 26.35% -44.29% -15.65% 14.78%
Operating Cash Flow Q/Q Growth		 1.87% -12.78% -3.84% -1.72% 0.76% -1.31% -5.97% -21.02% 1.68% -14.29% -5.29%
Free Cash Flow Firm Q/Q Growth		 -5.87% 3.03% -11.32% -6.20% 69.03% -145.20% -59.00% 7.35% -17.08% -32.18% 4.36%
Invested Capital Q/Q Growth		 183.06% 11.43% 0.44% -254.86% 8.06% 30.13% 65.70% -133.81% -12.17% 42.85% 1.82%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 51.51% 49.97% 49.94% 53.10% 100.00% 100.00% 100.00% 100.00% 100.01% 100.00% 100.00%
Interest Burden Percent		 100.01% 100.01% 99.91% 102.09% 117.35% 99.08% 101.52% 109.31% 92.48% 93.36% 93.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -146.99% -167.56% -234.41% -1,307.74% 2,756.54% -446.05% -124.92% -46.77% -38.99% -57.73% -52.56%
Cash Return on Invested Capital (CROIC)		 -884.55% -534.02% -625.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -146.99% -167.56% -234.41% -1,307.74% 2,756.54% -446.05% -124.92% -46.77% -38.99% -57.73% -52.56%
Return on Equity Simple (ROE_SIMPLE)		 -125.50% -170.25% -237.77% 753.90% -1,737.79% -276.08% -80.09% -27.47% -44.58% -56.58% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -21 -28 -39 -18 -14 -16 -29 -39 -49 -56
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 63.40% 126.20% 193.81% 649.42% -251.13% -55.45% -26.33% -13.26% -9.37% -15.61% -12.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - -34.50%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -30 -41 -55 -26 -21 -21 -38 -56 -73 -80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -29 -40 -54 -24 -21 -21 -35 -57 -76 -82
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 23.78 2.81 4.57 0.73 0.63 1.43 2.35
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 24.18 2.81 4.57 0.73 0.63 1.43 2.35
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.01 0.00 -0.87 0.00 0.00 0.54 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.54 0.00 0.00 0.00 0.00
Financial Leverage		 -0.74 -0.53 -0.49 -0.59 4.43 -2.36 -1.11 -1.01 -1.01 -1.04 -1.04
Leverage Ratio		 1.21 1.24 1.24 2.88 -6.68 2.55 1.60 1.11 1.04 1.08 1.09
Compound Leverage Factor		 1.21 1.24 1.24 2.94 -7.84 2.52 1.63 1.21 0.96 1.01 1.01
Debt to Total Capital		 1.92% 0.94% 0.12% -653.04% 0.00% 0.00% 34.86% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.67% 0.94% 0.12% -653.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.25% 0.00% 0.00% 0.00% 0.00% 0.00% 34.86% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.08% 99.06% 99.88% 753.04% 100.00% 100.00% 65.14% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 0.00 0.00 -0.06 0.00 0.00 -0.68 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.25 0.14 0.11 -0.03 0.00 0.00 1.32 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.68 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.01 0.00 0.00 -0.09 0.00 0.00 -0.87 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.37 0.19 0.16 -0.05 0.00 0.00 1.69 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.87 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -125.78 -18.74 -20.73 -1.66 20.51 2.32 4.60 13.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.59 2.60 2.78 0.32 1.45 3.26 21.34 61.78 20.18 13.39 14.37
Quick Ratio		 3.09 2.35 2.53 0.26 1.38 3.09 20.86 61.09 19.60 13.21 14.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -22 -28 -32 -11 -22 -18 -29 -38 -45 -56
Operating Cash Flow to CapEx		 -227.77% -501.41% -3,263.18% 0.00% 0.00% 0.00% 0.00% 0.00% -29,072.55% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -2,667.37 -4,410.77 -17,366.03 -25.06 -2.12 0.00 0.00 -16.56 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -1,052.00 -2,081.46 -8,345.74 -10.93 -3.09 0.00 0.00 -22.37 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,513.87 -2,496.58 -8,601.50 -9.74 -3.04 0.00 0.00 -22.37 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 5.63 6.61 11.67 14.39 17.76 11.34 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 64.79 55.26 31.28 25.36 20.56 32.18 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 3.51 4.81 4.05 -2.17 -9.82 -2.59 -0.98 -0.94 -2.19 -6.13 -5.73
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.97 1.29 -0.75 -6.23 -7.65 7.23 1.61 0.04 -1.26 -3.94 0.40
Enterprise Value (EV)		 0.00 0.00 0.00 30 30 11 92 -42 -45 45 214
Market Capitalization		 0.00 0.00 0.00 28 42 21 119 108 73 173 381
Book Value per Share		 $0.37 $0.36 $0.18 ($0.06) $0.01 $0.03 $3.12 $4.45 $3.15 $3.01 $1.90
Tangible Book Value per Share		 $0.37 $0.36 $0.18 ($0.06) $0.01 $0.03 $3.12 $4.45 $3.15 $3.01 $1.90
Total Capital		 9.23 8.86 8.54 -0.53 1.75 7.37 40 149 116 121 162
Total Debt		 0.18 0.08 0.01 3.44 0.00 0.00 14 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.02 0.00 0.00 0.00 0.00 0.00 14 0.00 0.00 0.00 0.00
Net Debt		 -5.55 -3.98 -4.48 1.79 -12 -9.96 -27 -150 -118 -127 -168
Capital Expenditures (CapEx)		 3.11 2.09 0.41 -1.54 -0.23 0.00 0.00 0.00 0.15 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.16 -1.22 -1.32 -2.45 -7.81 -2.66 -1.02 -0.77 -2.19 -7.83 -8.63
Debt-free Net Working Capital (DFNWC)		 4.56 2.84 3.17 -0.81 3.77 7.29 40 150 100 119 159
Net Working Capital (NWC)		 4.41 2.76 3.16 -4.24 3.77 7.29 40 150 100 119 159
Net Nonoperating Expense (NNE)		 -3.61 -6.00 -8.18 -8.72 12 5.97 4.88 12 13 19 18
Net Nonoperating Obligations (NNO)		 -5.54 -3.96 -4.47 1.79 -12 -9.96 -27 -150 -118 -127 -168
Total Depreciation and Amortization (D&A)		 0.13 0.75 1.11 1.07 2.10 0.02 0.01 2.51 -1.34 -2.80 -2.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.84) ($0.57) ($0.53) ($0.37) ($3.54) ($2.72) ($2.26) ($1.01) ($1.33) ($0.98)
Adjusted Weighted Average Basic Shares Outstanding		 24.34M 35.53M 53.73M 55.66M 293.32M 5.75M 8.62M 18.20M 51.19M 51.47M 76.00M
Adjusted Diluted Earnings per Share		 ($0.54) ($0.84) ($0.57) ($0.53) ($0.37) ($3.54) ($2.72) ($2.32) ($1.01) ($1.33) ($0.98)
Adjusted Weighted Average Diluted Shares Outstanding		 24.34M 35.53M 53.73M 55.66M 293.32M 5.75M 8.62M 19.49M 51.19M 51.47M 76.00M
Adjusted Basic & Diluted Earnings per Share		 ($0.54) ($0.84) ($0.57) ($0.53) ($0.37) ($3.54) ($2.72) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 20.95M 24.77M 41.30M 55.65M 88.87M 5.75M 7.67M 38.83M 36.83M 55.37M 90.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -21 -28 -37 -18 -14 -16 -29 -39 -49 -56
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3,278.12 -5,930.30 -25,477.57 -42.67 -5.23 0.00 0.00 -21.21 0.00 0.00 0.00
NOPAT to Interest Expense		 -2,225.74 -4,153.96 -17,839.29 -29.88 -3.66 0.00 0.00 -16.54 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -3,740.00 -6,345.42 -25,733.33 -41.47 -5.19 0.00 0.00 -21.21 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2,687.62 -4,569.08 -18,095.04 -28.69 -3.62 0.00 0.00 -16.54 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.43% -5.96% -3.37% -0.20% 0.00% -7.38% 0.00% 0.00% 0.00% 0.00% -1.42%

Quarterly Metrics And Ratios for Rezolute

This table displays calculated financial ratios and metrics derived from Rezolute's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 36,827,567.00 39,625,271.00 39,625,271.00 - - - 60,535,425.00 85,519,318.00 90,811,368.00 92,727,532.00 95,697,685.00
DEI Adjusted Shares Outstanding		 36,827,567.00 39,625,271.00 39,625,271.00 - - - 60,535,425.00 85,519,318.00 90,811,368.00 92,727,532.00 95,697,685.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.39 -0.35 -0.43 - - - -0.31 -0.29 -0.20 -0.25 -0.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -46.12% -20.54% -6.88% -66.64% -18.97% -2.51% -7.56% -5.72% -15.98% -40.13% 13.08%
EBIT Growth		 -55.68% -5.60% -5.92% -69.16% -6.45% -12.24% -10.22% -7.57% -16.96% -41.86% 13.30%
NOPAT Growth		 -55.74% -5.57% 5.42% -62.26% -6.45% -12.41% -23.50% -11.90% -16.98% -41.81% 13.27%
Net Income Growth		 -47.74% -2.60% -8.79% -80.52% -5.88% -13.09% -10.93% -6.15% -18.03% -44.78% 14.50%
EPS Growth		 -47.37% -3.85% -13.33% -69.23% 21.43% 18.52% 20.59% 38.64% 18.18% 0.00% 40.74%
Operating Cash Flow Growth		 -39.48% -73.76% 15.56% -63.19% -51.29% -4.96% -14.17% -18.75% -8.84% -48.72% 21.06%
Free Cash Flow Firm Growth		 -19.51% -114.19% 64.62% -40.40% -19.01% 12.13% -635.60% -51.23% -22.67% -69.74% 23.02%
Invested Capital Growth		 -168.67% 22.97% -448.77% -179.58% -32.45% -35.62% 45.62% 6.57% -14.64% 13.73% 41.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.63% -16.13% -9.94% -29.69% 28.15% -0.06% -15.37% -27.47% 21.17% -20.87% 28.44%
EBIT Q/Q Growth		 -12.18% 4.50% -19.46% -32.16% 29.40% -0.70% -17.31% -28.99% 23.24% -22.13% 28.30%
NOPAT Q/Q Growth		 -11.77% 4.52% -6.71% -42.49% 26.67% -0.82% -17.23% -29.10% 23.34% -22.22% 28.30%
Net Income Q/Q Growth		 -14.11% 4.23% -22.58% -34.76% 33.07% -2.29% -20.24% -28.95% 25.58% -25.48% 28.99%
EPS Q/Q Growth		 -7.69% 3.57% -25.93% -29.41% 50.00% 0.00% -22.73% 0.00% 33.33% -22.22% 27.27%
Operating Cash Flow Q/Q Growth		 6.74% -23.00% -17.06% -21.53% 13.54% 14.66% -27.32% -26.41% 20.75% -16.60% 32.42%
Free Cash Flow Firm Q/Q Growth		 -4.02% -31.26% 78.38% -375.73% 11.83% 3.08% -80.95% 2.19% 28.48% -34.10% 17.93%
Invested Capital Q/Q Growth		 -50.87% -27.55% -154.24% 42.85% 28.53% -30.61% -1.94% 1.82% 12.30% 1.71% 30.49%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.19% 91.43% 93.83% 95.67% 90.69% 92.13% 94.43% 94.41% 91.52% 94.03% 93.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -44.01% -48.79% -58.75% -57.73% -63.88% -74.36% -95.15% -52.56% -59.23% -74.02% -81.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.01% -48.79% -58.75% -57.73% -63.88% -74.36% -95.15% -52.56% -59.23% -74.02% -81.73%
Return on Equity Simple (ROE_SIMPLE)		 -54.54% -61.96% -82.15% 0.00% -61.10% -71.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -11 -11 -16 -12 -12 -14 -18 -14 -17 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.59% -2.70% -5.41% -5.54% -3.13% -3.75% -5.76% -4.27% -3.17% -4.89% -3.85%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.59% -16.02% - - -12.01% -16.98% -11.16% -9.43% -13.25% -10.40%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -15 -18 -24 -17 -17 -20 -26 -20 -24 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -17 -19 -25 -18 -18 -21 -26 -21 -25 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.47 0.43 1.43 1.43 2.37 2.85 2.13 2.35 5.80 1.71 2.50
Price to Tangible Book Value (P/TBV)		 0.47 0.43 1.43 1.43 2.37 2.85 2.13 2.35 5.80 1.71 2.50
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.06 -1.04 -1.04 -1.05 -1.11 -1.04 -1.04 -1.05 -1.05
Leverage Ratio		 1.05 1.08 1.12 1.08 1.09 1.12 1.19 1.09 1.08 1.10 1.10
Compound Leverage Factor		 0.96 0.99 1.05 1.03 0.99 1.03 1.12 1.03 0.99 1.04 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.23 -1.16 -0.95 5.83 12.78 9.65 3.34 14.51 41.51 8.37 15.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.27 12.00 11.82 13.39 13.79 9.30 8.43 14.37 15.15 14.18 15.84
Quick Ratio		 13.72 11.56 11.50 13.21 13.55 9.10 8.25 14.09 14.91 13.95 15.61
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.06 -12 -2.57 -12 -11 -10 -19 -18 -13 -18 -15
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.31 -4.22 -11 -6.13 -4.38 -5.73 -5.84 -5.73 -5.03 -4.94 -3.43
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.08 1.26 -8.78 -3.94 -1.07 -1.50 4.90 0.40 -0.64 0.79 2.40
Enterprise Value (EV)		 -58 -57 19 45 151 179 87 214 701 86 172
Market Capitalization		 49 39 101 173 269 284 176 381 854 219 292
Book Value per Share		 $2.81 $2.31 $1.79 $3.01 $2.05 $1.72 $1.36 $1.90 $1.62 $1.38 $1.22
Tangible Book Value per Share		 $2.81 $2.31 $1.79 $3.01 $2.05 $1.72 $1.36 $1.90 $1.62 $1.38 $1.22
Total Capital		 104 92 71 121 113 100 83 162 147 128 117
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -107 -96 -82 -127 -118 -105 -88 -168 -152 -133 -120
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.28 -4.52 -4.77 -7.83 -6.09 -8.45 -8.68 -8.63 -7.70 -7.36 -5.92
Debt-free Net Working Capital (DFNWC)		 95 88 75 119 102 88 78 159 144 126 114
Net Working Capital (NWC)		 95 88 75 119 102 88 78 159 144 126 114
Net Nonoperating Expense (NNE)		 3.38 3.27 5.70 6.80 3.52 3.77 4.90 6.30 4.28 5.82 4.01
Net Nonoperating Obligations (NNO)		 -107 -96 -82 -127 -118 -105 -88 -168 -152 -133 -120
Total Depreciation and Amortization (D&A)		 0.98 -2.14 -0.91 -0.73 -0.82 -0.72 -0.50 -0.33 -0.79 -0.71 -0.47
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.28) ($0.27) ($0.34) ($0.44) ($0.22) ($0.22) ($0.27) ($0.27) ($0.18) ($0.22) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 51.41M 51.41M 50.81M 51.47M 69.74M 69.94M 70.03M 76.00M 103.42M 103.69M 104.04M
Adjusted Diluted Earnings per Share		 ($0.28) ($0.27) ($0.34) ($0.44) ($0.22) ($0.22) ($0.27) ($0.27) ($0.18) ($0.22) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 51.41M 51.41M 50.81M 51.47M 69.74M 69.94M 70.03M 76.00M 103.42M 103.69M 104.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 39.63M 39.63M 40.14M 55.37M 57.94M 60.54M 85.52M 90.81M 92.73M 95.70M 96.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -11 -11 -16 -12 -12 -14 -18 -14 -17 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.51% 0.00% -0.84% -0.43% -0.84% -1.42% -0.67% -0.59% -0.61%

Financials Breakdown Chart

Key Financial Trends

Rezolute (NASDAQ: RZLT) remains a pre-revenue biotech story with no product sales, ongoing operating losses, and a balance sheet that is still supported by a large cash and investment position. Over the last four quarters, the company has continued to burn cash on research and development, while financing activity and investment income have helped offset some of that pressure.

Top trends from the last several quarters:

  • Rezolute finished Q3 2026 with $120.3 million in cash and short-term investments, giving it substantial liquidity for a clinical-stage company.
  • The company still had more current assets than total liabilities in Q3 2026, with current assets of $122.0 million versus total liabilities of $8.6 million.
  • Interest and investment income has been meaningful, generating $1.2 million in Q3 2026 and helping reduce the quarterly pretax loss.
  • Operating cash burn improved sequentially in Q3 2026, with operating cash use of $13.7 million versus $20.3 million in Q2 2026.
  • Rezolute has continued to raise capital when needed, including a large issuance of common equity in Q4 2025 that produced over $101 million in financing cash flow.
  • Revenue remains $0 across every quarter provided, so the investment case still depends on pipeline progress rather than commercial performance.
  • R&D spending remains elevated, which is typical for a biotech company but also means the business is still far from profitability.
  • Shares outstanding have trended upward over time, reflecting dilution risk for existing shareholders as the company funds operations.
  • Q3 2026 net loss was $16.2 million, and the company has posted losses in every quarter shown.
  • Operating cash flow was negative in each of the last four reported quarters, indicating the business is still consuming cash to fund operations.

Income statement trends: Rezolute has reported no revenue in each quarter shown, while operating expenses have stayed high due to research and development. In Q3 2026, total operating expenses were $17.4 million, down from $24.2 million in Q2 2026 and $25.9 million in Q4 2025, but still sizable relative to the company’s cash-generating ability. The quarterly net loss improved from $22.8 million in Q2 2026 to $16.2 million in Q3 2026.

Cash flow trends: The company’s operating cash burn has been persistent, ranging from about $10.6 million to $22.0 million per quarter in the periods shown. Investing cash flow has been volatile because it is largely driven by purchases and maturities of marketable securities, not core business operations. Financing activity was especially important in Q4 2025, when Rezolute raised substantial equity capital, boosting liquidity and strengthening the balance sheet.

Balance sheet trends: Rezolute’s liquidity position improved sharply after the Q4 2025 capital raise, with total assets rising to $158.7 million in Q1 2026 before easing to $125.5 million in Q3 2026 as cash and investments were used to fund operations. Total liabilities remained modest at $8.6 million in Q3 2026, so leverage is not a concern right now. However, retained earnings remain deeply negative, reflecting the company’s long history of losses.

Bottom line: Rezolute looks financially stable in the near term thanks to its cash and investment balance, but it is still a classic clinical-stage biotech profile: no revenue, recurring losses, and ongoing cash burn. Investors will likely focus less on quarterly earnings and more on whether the company can advance its pipeline toward a value-driving milestone before needing additional financing.

07/13/26 11:26 PM ETAI Generated. May Contain Errors.

Rezolute Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rezolute's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Rezolute's net income appears to be on an upward trend, with a most recent value of -$74.41 million in 2025, rising from -$11.36 million in 2015. The previous period was -$68.46 million in 2024. Check out Rezolute's forecast to explore projected trends and price targets.

Rezolute's total operating income in 2025 was -$79.89 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $79.89 million

Over the last 10 years, Rezolute's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Rezolute's total liabilities were at $13.36 million at the end of 2025, a 13.9% increase from 2024, and a 504.8% increase since 2015.

In the past 10 years, Rezolute's cash and equivalents has ranged from $1.65 million in 2018 to $150.41 million in 2022, and is currently $94.11 million as of their latest financial filing in 2025.

Over the last 10 years, Rezolute's book value per share changed from 0.37 in 2015 to 1.90 in 2025, a change of 409.6%.


Related Companies

Financial statements for NASDAQ:RZLT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel